Nuclear medicine imaging can be broadly divided into direct photon emission imaging encompassing planar scintigraphy and single photon emission tomography (SPECT) on one hand, and positron emission tomography (PET) on the other. PET is often used in combination with computed tomography (CT), yielding hybrid studies with a widespread and increasing use.
99mTc-DMSA scintigraphy is the most widely used functional imaging procedure of the renal cortex. It is usually performed as planar imaging with anteroposterior and oblique projections, rendering 2D images read for signs of damage to the parenchyma, as well as semi-automatic calculation of split renal function percentages.
Biodistribution studies of 68Ga and 18F labeled PSMA ligand compounds used for PET imaging of prostate cancer show a substantial renal uptake. This may potentially allow high resolution 3D functional imaging of the renal cortex using PET. Using 68Ga-PSMA-11 PET/CT for this purpose has been suggested and early but promising results have been published from studies on this radiotracer. 18F-PSMA-1007 PET/CT is routinely used for staging and detection of recurrence in prostate cancer patients at Skåne University Hospital, but its potential use for renal parenchymal functional imaging has not yet been explored.
The overall aim of the project is to evaluate 18F-PSMA-1007 PET for renal cortical functional imaging.